The survival of spirochetes from the Borrelia burgdorferi (sensu lato) complex in a hostile environment is achieved by the regulation of differential gene expression in response to changes in temperature, salts, nutrient content, acidity fluctuation, multiple host or vector dependent factors, and leads to the formation of dormant subpopulations of cells. From the other side, alterations in the level of gene expression in response to antibiotic pressure leads to the establishment of a persisters subpopulation. Both subpopulations represent the cells in different physiological states. "Dormancy" and "persistence" do share some similarities, e.g. both represent cells with low metabolic activity that can exist for extended periods without replication, both constitute populations with different gene expression profiles and both differ significantly from replicating forms of spirochetes. Persisters are elusive, present in low numbers, morphologically heterogeneous, multi-drug-tolerant cells that can change with the environment. The definition of "persisters" substituted the originally-used term "survivors", referring to the small bacterial population of Staphylococcus that survived killing by penicillin. The phenomenon of persisters is present in almost all bacterial species; however, the reasons why Borrelia persisters form are poorly understood. Persisters can adopt varying sizes and shapes, changing from well-known forms to altered morphologies. They are capable of forming round bodies, L-form bacteria, microcolonies or biofilms-like aggregates, which remarkably change the response of Borrelia to hostile environments. Persisters remain viable despite aggressive antibiotic challenge and are able to reversibly convert into motile forms in a favorable growth environment. Persisters are present in significant numbers in biofilms, which has led to the explanation of biofilm tolerance to antibiotics. Considering that biofilms are associated with numerous chronic diseases through their resilient presence in the human body, it is not surprising that interest in persisting cells has consequently accelerated. Certain diseases caused by pathogenic bacteria (e.g. tuberculosis, syphilis or leprosy) are commonly chronic in nature and often recur despite antibiotic treatment. Three decades of basic and clinical research have not yet provided a definite answer to the question: is there a connection between persisting spirochetes and recurrence of Lyme disease in patients?

Biology Centre CAS Institute of Parasitology Branisovska 31 37005 Ceske Budejovice Czech Republic

National Institute of Public Health Srobarova 48 100 42 Prague 10 Czech Republic

Zobrazit více v PubMed

Singh SK, Girschick HJ. Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi. Lancet Infect Dis. 2004;4:575–583. doi: 10.1016/S1473-3099(04)01132-6. PubMed DOI

Hovius J, van Dam AP, Fikrig E. Tick–host–pathogen interactions in Lyme borreliosis. Trends Parasitol. 2007;23:434–438. doi: 10.1016/j.pt.2007.07.001. PubMed DOI

Fikrif E, Narasimhan S. Borrelia burgdorferi-traveling incognito? Microb Infect. 2006;8:1390–1399. doi: 10.1016/j.micinf.2005.12.022. PubMed DOI

Kraiczy P. Hide and seek: how Lyme disease spirochetes overcome complement attack. Front Immunol. 2016;7:385. doi: 10.3389/fimmu.2016.00385. PubMed DOI PMC

Dunham-Ems SM, Caimano MJ, Pal U, Wolgemuth CW, Eggers CH, Balic A, et al. Live imaging reveals a biphasic mode of dissemination of Borrelia burgdorferi within ticks. J Clin Investig. 2009;119:3652–3665. doi: 10.1172/JCI39401. PubMed DOI PMC

Samuels DS. Gene regulation in Borrelia burgdorferi. Annu Rev Microbiol. 2011;2011(65):479–499. doi: 10.1146/annurev.micro.112408.134040. PubMed DOI

Drecktrah D, Lybecker M, Popitsch N, Rescheneder P, Hall LS, Samuels DS. The Borrelia burgdorferi RelA/SpoT homolog and stringent response regulate survival in the tick vector and global gene expression during starvation. PLoS Pathog. 2015;11:e1005160. doi: 10.1371/journal.ppat.1005160. PubMed DOI PMC

Brorson O, Brorson SH. A rapid method for generating cystic forms of Borrelia burgdorferi and their reversal to mobile spirochetes. APMIS. 1998;106:1131–1141. doi: 10.1111/j.1699-0463.1998.tb00269.x. PubMed DOI

Akins DR, Bourell KW, Caimano MJ, Norgard MV, Radolf JD. A new animal model for studying Lyme disease spirochetes in a mammalian host-adapted state. J Clin Investig. 1998;101:2240–2250. doi: 10.1172/JCI2325. PubMed DOI PMC

Carroll JA, Garon CF, Schwan TG. Effects of environmental pH on membrane proteins of Borrelia burgdorferi. Infect Immun. 1999;67:3181–3187. PubMed PMC

Hodzic E, Feng S, Freet KJ, Barthold SW. Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect Immun. 2003;71:5042–5055. doi: 10.1128/IAI.71.9.5042-5055.2003. PubMed DOI PMC

Feng J, Shi W, Zhang S, Zhang YP. Persister mechanisms in Borrelia burgdorferi: implications for improved intervention. EMI. 2015;4:e51. PubMed PMC

Wu Q, Guan G, Liu Z, Li Y, Luo J, Yin H. RNA-Seq-based analysis of changes in Borrelia burgdorferi gene expression linked to pathogenicity. Parasites Vectors. 2015;8:155. doi: 10.1186/s13071-014-0623-2. PubMed DOI PMC

Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology. 2000;146:119–127. doi: 10.1099/00221287-146-1-119. PubMed DOI

Gruntar I, Malovrh T, Murgia R, Cinco M. Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS. 2001;109:383–388. doi: 10.1034/j.1600-0463.2001.090507.x. PubMed DOI

Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357–372. doi: 10.1146/annurev.micro.112408.134306. PubMed DOI

Hodzic E, Imai D, Feng S, Barthold SW. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. PLoS ONE. 2014;9:e86907. doi: 10.1371/journal.pone.0086907. PubMed DOI PMC

Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother. 2015;59:4616–4624. doi: 10.1128/AAC.00864-15. PubMed DOI PMC

Cabello FC, Godfrey HP, Newman SA. Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol. 2007;15:350–354. doi: 10.1016/j.tim.2007.06.003. PubMed DOI

Tilly K, Rosa PA, Stewart PE. Biology of infection with Borrelia burgdorferi. Infect Dis Clin N Am. 2007;22:217–234. doi: 10.1016/j.idc.2007.12.013. PubMed DOI PMC

Liang FT, Brown EL, Wang T, Iozzo RV, Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol. 2004;165:977–985. doi: 10.1016/S0002-9440(10)63359-7. PubMed DOI PMC

Yrjänäinen H, Hytonen J, Soderstrom KO, Oksi J, Hartiala K, Viljanen MK. Persistent joint swelling and Borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment. Microbes Infect. 2006;8:2044–2051. doi: 10.1016/j.micinf.2006.03.008. PubMed DOI

Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother. 2008;52:1728–1736. doi: 10.1128/AAC.01050-07. PubMed DOI PMC

Barthold SW, deSouza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol. 1993;143:951–971. PubMed PMC

Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother. 2010;54:643–651. doi: 10.1128/AAC.00788-09. PubMed DOI PMC

Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Investig. 2012;122:2652–2660. doi: 10.1172/JCI58813. PubMed DOI PMC

Yrjänäinen H, Hytönen J, Song XR, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-α treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J Infect Dis. 2007;195:1489–1496. doi: 10.1086/513873. PubMed DOI

Yrjänäinen H, Hytönen J, Hartiala P, Oksi J, Viljanen MK. Borrelia burgdorferi DNA in joints and tissue adjacent to the joint is the niche of persisting burgdorferi in ceftriaxone-treated mice. APMIS. 2010;118:665–673. doi: 10.1111/j.1600-0463.2010.02615.x. PubMed DOI

Baum E, Hue F, Barbour AG. Experimental infections of the reservoir species Peromyscus leucopus with diverse strains of Borrelia burgdorferi, a Lyme disease agent. MBio. 2012;3:e00434-12. doi: 10.1128/mBio.00434-12. PubMed DOI PMC

Schwan TG, Burgdorfer W, Schrumpf ME, Karstens RH. The urinary bladder: a consistent source of Borrelia burgdorferi in experimentally infected white-footed mice (Peromyscus leucopus) J Clin Microbiol. 1988;26:893–895. PubMed PMC

Moody KD, Barthold SW, Terwilliger GA, Beck DS, Hansen GM, Jacoby RO. Experimental chronic Lyme borreliosis in Lewis rats. Am J Trop Med Hyg. 1990;42:65–74. doi: 10.4269/ajtmh.1990.42.165. PubMed DOI

Duray PH, Johnson RC. The histopathology of experimentally infected hamsters with the Lyme disease spirochete, Borrelia burgdorferi. Proc Soc Exp Biol Med. 1986;181:263–269. doi: 10.3181/00379727-181-42251. PubMed DOI

Goodman JL, Jurkovich P, Kodner C, Johnson RC. Persistent cardiac and urinary tract infections with Borrelia burgdorferi in experimentally infected Syrian hamsters. J Clin Microbiol. 1991;29:894–896. PubMed PMC

Sonnesyn SW, Manivel JC, Johnson RC, Goodman JL. A guinea pig model for Lyme disease. Infect Immun. 1993;61:4777–4778. PubMed PMC

Schmitz JL, Schell RF, Lovrich SD, Callister SM, Coe JE. Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters. Infect Immun. 1991;59:1916–1921. PubMed PMC

Preac-Mursic V, Patsouris E, Wilske B, Reinhardt S, Gos B, Mehraein P. Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals; comparison with histopathological findings in human Lyme disease. Infection. 1990;18:332–341. doi: 10.1007/BF01646399. PubMed DOI

Straubinger RK, Summers BA, Chang YF, Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol. 1997;35:111–116. PubMed PMC

Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J Infect Dis. 2000;181:1069–1081. doi: 10.1086/315340. PubMed DOI

Straubinger RK, Straubinger AF, Jacobson RH, Chang Y, Summers BA, Erb HN, et al. Two lessons from the canine model of Lyme disease: migration of Borrelia burgdorferi in tissues and persistence after antibiotic treatment. J Spirochetal Tick Borne Dis. 1997;4:24–31.

Chang YF, Ku YW, Chang CF, Chang CD, McDonough SP, Divers T, et al. Antibiotic treatment of experimentally Borrelia burgdorferi-infected ponies. Vet Microbiol. 2005;107:285–294. doi: 10.1016/j.vetmic.2005.02.006. PubMed DOI

Imai DM, Barr BC, Daft B, Bertone JJ, Feng S, Hodzic E, et al. Lyme neuroborreliosis in 2 horses. Vet Pathol. 2011;48:1151–1157. doi: 10.1177/0300985811398246. PubMed DOI

James FM, Engiles JB, Beech J. Meningitis, cranial neuritis, and radiculoneuritis associated with Borrelia burgdorferi infection in a horse. J Am Vet Med A. 2010;10:1180–1185. doi: 10.2460/javma.237.10.1180. PubMed DOI

Embers ME, Hasenkampf NR, Jacobs MB, Tardo AC, Doyle-Meyers LA, Philipp MT, et al. Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS ONE. 2017;12:e0189071. doi: 10.1371/journal.pone.0189071. PubMed DOI PMC

Roberts ED, Bohm RP, Jr, Cogswell FB, Lanners HN, Lowrie RC, Jr, et al. Chronic Lyme disease in the rhesus monkey. Lab Investig. 1995;72:146–160. PubMed

Roberts ED, Bohm RP, Jr, Lowrie RC, Jr, Habicht G, Katona L, Piesman J, et al. Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: the early disseminated and chronic phases of disease in the peripheral nervous system. J Infect Dis. 1998;178:722–732. doi: 10.1086/515357. PubMed DOI

Cadavid D, Bai Y, Hodzic E, Narayan K, Barthold SW, Pachner AR. Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi. Lab Investig. 2004;84:1439–1450. doi: 10.1038/labinvest.3700177. PubMed DOI

Hefty PS, Brooks CS, Jett AM, White GL, Wikel SK, Kennedy RC, et al. OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human Lyme disease patients. J Clin Microbiol. 2002;40:4256–4265. doi: 10.1128/JCM.40.11.4256-4265.2002. PubMed DOI PMC

Stricker RB, Johnson L. Persistent infection in chronic Lyme disease: does form matter? Res J Infect Dis. 2013;1:2. doi: 10.7243/2052-5958-1-2. DOI

Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE. 2012;7:e29914. doi: 10.1371/journal.pone.0029914. PubMed DOI PMC

Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase PW, Andiman WA. Erythema chronicum migrans and Lyme arthritis: the enlarging clinical spectrum. Ann Intern Med. 1977;86:685–698. doi: 10.7326/0003-4819-86-6-685. PubMed DOI

Middelveen MJ, Sapi E, Burke J, Filush KR, Franco A, Fesler MC, et al. Persistent borrelia infection in patients with ongoing symptoms of Lyme disease. Healthcare. 2018;6:33. doi: 10.3390/healthcare6020033. PubMed DOI PMC

Berger BW. Treating erythema chronicum migrans of Lyme disease. J Am Acad Dermatol. 1986;3:459–463. doi: 10.1016/S0190-9622(86)70194-1. PubMed DOI

Liegner KB, Shapiro JR, Ramsay D, Halperin AJ, Hogrefe W, Kong L. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting Borrelia burgdorferi. J Am Acad Dermatol. 1993;28:312–314. doi: 10.1016/0190-9622(93)70043-S. PubMed DOI

Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Inf Dis. 1988;158:905–906. doi: 10.1093/infdis/158.4.905. PubMed DOI

Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte response to Borrelia burgdorferi. N Engl J Med. 1988;319:1441–1446. doi: 10.1056/NEJM198812013192203. PubMed DOI

Weber K, Bratzke HJ, Neubert U, Wilske B, Duray PH. Borrelia burgdorferi in a newborn despite oral penicillin for Lyme borreliosis during pregnancy. Pediatr Infect Dis J. 1988;7:286–289. doi: 10.1097/00006454-198804000-00010. PubMed DOI

Steere AC, Duray PH, Butcher EC. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum. 1988;31:487–495. doi: 10.1002/art.1780310405. PubMed DOI

Preac-Mursic V, Weber K, Pfister HW, Wilske B, Gross B, Baumann A, et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection. 1989;17:355–359. doi: 10.1007/BF01645543. PubMed DOI

Girschick HJ, Huppertz HI, Rüssmann H, Krenn V, Karch H. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int. 1996;16:125–132. doi: 10.1007/BF01409985. PubMed DOI

Cimmino MA, Azzolini A, Tobia F, Pesce CM. Spirochetes in the spleen of a patient with chronic Lyme disease. Am J Clin Pathol. 1989;91:95–97. doi: 10.1093/ajcp/91.1.95. PubMed DOI

Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KMJ. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. Infect Dis. 1991;163:311–318. doi: 10.1093/infdis/163.2.311. PubMed DOI

Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990;323:1438–1444. doi: 10.1056/NEJM199011223232102. PubMed DOI

Battafarano DF, Combs JA, Enzenauer RJ, Fitzpatrick JE. Chronic septic arthritis caused by Borrelia burgdorferi. Clin Orthop. 1993;297:238–241. PubMed

Häupl T, Hahn G, Rittig M, Krause A, Schoerner C, Schonherr U, et al. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 1993;36:1621–1626. doi: 10.1002/art.1780361118. PubMed DOI

Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993;21:83–88. doi: 10.1007/BF01710737. PubMed DOI

Preac-Mursic V, Pfister HW, Spiegel H, Burk R, Wilske B, Reinhardt S, et al. First isolation of Borrelia burgdorferi from an iris biopsy. J Clin Neuroophthalmol. 1993;13:155–161. PubMed

Strle F, Maraspin V, Lotric-Furlan S, Ruziç-Sabljiç E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection. 1996;24:64–68. doi: 10.1007/BF01780661. PubMed DOI

Preac-Mursic V, Marget W, Busch U, Pleterski Rigler D, Hagl S. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection. 1996;24:9–16. doi: 10.1007/BF01780643. PubMed DOI

Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP, et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Int Med. 1994;121:560–567. doi: 10.7326/0003-4819-121-8-199410150-00002. PubMed DOI

Oksi J, Kalimo H, Marttila RJ, Marjamäki M, Sonninen P, Nikoskelainen J, et al. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature. Brain. 1996;119:2143–2154. doi: 10.1093/brain/119.6.2143. PubMed DOI

Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A. Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis. 1998;57:118–121. doi: 10.1136/ard.57.2.118. PubMed DOI PMC

Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med. 1999;31:225–232. doi: 10.3109/07853899909115982. PubMed DOI

Weber K. Treatment failure in erythema migrans: a review. Infection. 1996;24:73–75. doi: 10.1007/BF01780663. PubMed DOI

Honegr K, Hulínská D, Beran J, Dostál V, Havlasová J, Čermáková Z. Long term and repeated electron microscopy and PCR detection of Borrelia burgdorferi sensu lato after an antibiotic treatment. Cent Eur J Public Health. 2004;12:6–11. PubMed

Breier F, Khanakah G, Stanek G, Kunz G, Aberer E, Schmidt B, et al. Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br J Dermatol. 2001;144:387–392. doi: 10.1046/j.1365-2133.2001.04034.x. PubMed DOI

Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother. 2005;49:1294–1301. doi: 10.1128/AAC.49.4.1294-1301.2005. PubMed DOI PMC

Hudson BJ, Stewart M, Lennox VA, Fukunaga M, Yabuki M, Macorison H, et al. Culture-positive Lyme borreliosis. Med J Aust. 1998;168:500–502. doi: 10.5694/j.1326-5377.1998.tb141415.x. PubMed DOI

Kirsch M, Ruben FL, Steere AC, Duray PH, Norden CW, Winkelstein A. Fatal adult respiratory distress syndrome in a patient with Lyme disease. J Am Med Assoc. 1988;259:2737–2739. doi: 10.1001/jama.1988.03720180063034. PubMed DOI

Chancellor MB, McGinnis DE, Shenot PJ, Kiilholma P, Hirsch IH. Urinary dysfunction in Lyme disease. J Urol. 1993;149:26–30. doi: 10.1016/S0022-5347(17)35989-X. PubMed DOI

Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med. 1994;330:229–234. doi: 10.1056/NEJM199401273300401. PubMed DOI

Masters E. Spirochetemia after continuous high-dose oral amoxicillin therapy. Infect Dis Clin Pract. 1994;3:207–208. doi: 10.1097/00019048-199405000-00016. DOI

Lawrence C, Lipton RB, Lowy FD, Coyle PK. Seronegative chronic relapsing neuroborreliosis. Eur Neurol. 1995;35:113–117. doi: 10.1159/000117104. PubMed DOI

Bayer ME, Zhang L, Bayer MH. Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases. Infection. 1996;24:347–353. doi: 10.1007/BF01716077. PubMed DOI

Nocton JJ, Bloom BJ, Rutledge BJ. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis. 1996;174:623–627. doi: 10.1093/infdis/174.3.623. PubMed DOI

Rudenko N, Golovchenko M, Vancova M, Clark K, Grubhoffer L, Oliver JH., Jr Isolation of live Borrelia burgdorferi sensu lato spirochetes from patients with undefined disorders and symptoms not typical for Lyme diseases. Clin Microbiol Infect. 2016;22:267.e9–267.e15. doi: 10.1016/j.cmi.2015.11.009. PubMed DOI

Shapiro ED. Repeat or persistent Lyme disease: persistence, recrudescence or reinfection with Borrelia burgdorferi? F1000Prime Rep. 2015;7:11. doi: 10.12703/P7-11. PubMed DOI PMC

Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microb Infect. 2004;6:312–318. doi: 10.1016/j.micinf.2003.11.014. PubMed DOI

Steere AC. Lyme disease. N Engl J Med. 2001;345:115–125. doi: 10.1056/NEJM200107123450207. PubMed DOI

Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–1134. doi: 10.1086/508667. PubMed DOI

Hu LT. In the clinic. Lyme disease. Ann Intern Med. 2012;157:ITC2-2–ITC2-16. doi: 10.7326/0003-4819-157-3-201208070-01002. PubMed DOI

Hobby GL, Meyer K, Chaffee E. Observations on the mechanism of action of penicillin. Exp Biol Med. 1942;50:281–285. doi: 10.3181/00379727-50-13773. DOI

Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilization. Lancet. 1944;244:497–500. doi: 10.1016/S0140-6736(00)74210-3. DOI

Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230:13–18. doi: 10.1016/S0378-1097(03)00856-5. PubMed DOI

Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60:699–709. doi: 10.1099/jmm.0.030932-0. PubMed DOI

Zhang Y. Persisters, persistent infections and the Yin-Yang model. Emerg Microbes Infect. 2014;3:e3. PubMed PMC

Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS ONE. 2012;7:e48277. doi: 10.1371/journal.pone.0048277. PubMed DOI PMC

Kurtti TJ, Munderloh UG, Johnson RC, Ahlstrand GG. Colony formation and morphology in Borrelia burgdorferi. J Clin Microbiol. 1987;25:2054–2058. PubMed PMC

Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol. 1996;18:571–579. doi: 10.1097/00000372-199612000-00004. PubMed DOI

Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection. 1996;24:218–226. doi: 10.1007/BF01781096. PubMed DOI

Brorson O, Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection. 1997;25:240–246. doi: 10.1007/BF01713153. PubMed DOI

Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme borreliosis. J Neuroinflamm. 2008;5:40. doi: 10.1186/1742-2094-5-40. PubMed DOI PMC

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97–113. PubMed PMC

Meriläinen L, Herranen A, Schwarzbach A, Gilbert L. Morphological and biochemical features of Borrelia burgdorferi pleomorphic form. Microbiology. 2015;161:516–527. doi: 10.1099/mic.0.000027. PubMed DOI PMC

Murgia R, Cinco M. Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS. 2004;112:57–62. doi: 10.1111/j.1600-0463.2004.apm1120110.x. PubMed DOI

Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother. 1995;39:1127–1133. doi: 10.1128/AAC.39.5.1127. PubMed DOI PMC

Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA. 2009;106:18656–18661. doi: 10.1073/pnas.0908236106. PubMed DOI PMC

Caskey JR, Embers ME. Persister development by Borrelia burgdorferi populations in vitro. Antimicrob Agents Chemother. 2015;59:6288–6295. doi: 10.1128/AAC.00883-15. PubMed DOI PMC

Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. EMI. 2014;3:e49. PubMed PMC

Feng J, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y. A drug combination screen identifies drugs active against amoxicillin-induced round bodies of in vitro Borrelia burgdorferi persisters from an FDA drug library. Front Microbiol. 2016;7:743. PubMed PMC

Dubinina G, Grabovich M, Leshcheva N, Rainey FA, Gavrish E. Spirochaeta perfilievii sp. nov., a novel oxygen-tolerant, sulfide oxidizing, sulfur and thiosulfate reducing spirochete isolated from a saline spring. Int J Syst Evol Microbiol. 2011;61:110–117. doi: 10.1099/ijs.0.018333-0. PubMed DOI

Droge S, Frohlich J, Radek R, Konig H. Spirochaeta coccoides sp. nov., a novel coccoid spirochete from the hindgut of the termite Neotermes castaneus. Appl Environ Microbiol. 2006;72:391–397. PubMed PMC

Dutton JE, Todd JL. The nature of human tick fever in the eastern part of the Congo Free State. Liverpool Sch Trop Med Hyg. 1905;17:1–18.

Hoogenraad NJ, Hird FJR, Holmes I, Millis NF. Bacteriophages in rumen contents of sheep. J Gen Virol. 1967;1:575–576. doi: 10.1099/0022-1317-1-4-575. PubMed DOI

Sapi E, Balasubramanian K, Poruri A, Maghsoudlou JS, Theophilus PAS, Socarras KM, et al. Evidence of in vivo existence of Borrelia biofilm in borrelial lymphocytomas. Eur J Microbiol Immunol. 2016;6:9–24. doi: 10.1556/1886.2015.00049. PubMed DOI PMC

Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G Ital Dermatol Venereol. 2009;144:157–171. PubMed

Olivares J, Bernardini A, Garcia-Leon G, Corona FB, Sanchez M, Martinez JL. The intrinsic resistome of bacterial pathogens. Front Microbiol. 2013;4:103. doi: 10.3389/fmicb.2013.00103. PubMed DOI PMC

Feng J, Auwaerter PG, Zhang Y. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS ONE. 2015;10:e0117207. doi: 10.1371/journal.pone.0117207. PubMed DOI PMC

Jefferson KK. What drives bacteria to produce biofilm? FEMS Microbiol Lett. 2004;236:163–173. doi: 10.1111/j.1574-6968.2004.tb09643.x. PubMed DOI

Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193. doi: 10.1128/CMR.15.2.167-193.2002. PubMed DOI PMC

Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999–1007. doi: 10.1128/AAC.45.4.999-1007.2001. PubMed DOI PMC

O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49–79. doi: 10.1146/annurev.micro.54.1.49. PubMed DOI

Costerton JW, Geesey GG, Cheng KJ. How bacteria stick. Sci Am. 1978;238:86–95. doi: 10.1038/scientificamerican0178-86. PubMed DOI

Vesey PM, Kuramitsu HK. Genetic analysis of Treponema denticola ATCC 35405 biofilm formation. Microbiol. 2004;150:2401–2407. doi: 10.1099/mic.0.26816-0. PubMed DOI

Ristow P, Bourhy P, Kerneis S, Schmitt C, Prevost M-C, Lilenbaum W, et al. Biofilm formation by saprophytic and pathogenic leptospires. Microbiol. 2008;154:1309–1317. doi: 10.1099/mic.0.2007/014746-0. PubMed DOI

Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745. doi: 10.1146/annurev.mi.49.100195.003431. PubMed DOI

Bayer AS, Speert DP, Park S, Tu J, Witt M, Nast CC, et al. Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa. Infect Immun. 1991;59:302–308. PubMed PMC

Gacesa P. Bacterial alginate biosynthesis: recent progress and future prospects. Microbiology. 1998;144:1133–1143. doi: 10.1099/00221287-144-5-1133. PubMed DOI

Mah T-FC, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;1:34–39. doi: 10.1016/S0966-842X(00)01913-2. PubMed DOI

Costerton JW, Stewart PS, Greenburg EP. Bacterial biofilms, a common cause of persistent infections. Science. 1999;284:1318–1322. doi: 10.1126/science.284.5418.1318. PubMed DOI

Branda SS, Vik S, Friedman L, Kolter R. Biofilms: the matrix revisited. Trends Microbiol. 2005;13:20–26. doi: 10.1016/j.tim.2004.11.006. PubMed DOI

Remminghorst U, Rehm BHA. Bacterial alginates: from biosynthesis to applications. Biotechnol Lett. 2006;28:1701–1712. doi: 10.1007/s10529-006-9156-x. PubMed DOI

Kazmierczak MJ, Wiedmann M, Boor KJ. Alternative sigma factors and their roles in bacterial virulence. Microbiol Mol Biol Rev. 2005;69:527–543. doi: 10.1128/MMBR.69.4.527-543.2005. PubMed DOI PMC

Ouyang Z, Narasimhan S, Neelakanta G, Kumar M, Pal U, Fikrig E, et al. Activation of the RpoN–RpoS regulatory pathway during the enzootic life cycle of Borrelia burgdorferi. BMC Microbiol. 2012;12:44. doi: 10.1186/1471-2180-12-44. PubMed DOI PMC

Dunham-Ems SM, Caimano MJ, Eggers CH, Radolf JD. Borrelia burgdorferi requires the alternative sigma factor RpoS for dissemination within the vector during tick-to mammal transmission. PLoS Pathog. 2012;8:e1002532. doi: 10.1371/journal.ppat.1002532. PubMed DOI PMC

Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005;21:319–346. doi: 10.1146/annurev.cellbio.21.012704.131001. PubMed DOI

Bassler BL. How bacteria talk to each other: regulation of gene expression by quorum sensing. Curr Opin Microbiol. 1999;2:582–587. doi: 10.1016/S1369-5274(99)00025-9. PubMed DOI

Schauder S, Shokat K, Surette MG, Bassler BL. The LuxS family of bacterial autoinducers: biosynthesis of a novel quorum-sensing signal molecule. Mol Microbiol. 2001;41:463–476. doi: 10.1046/j.1365-2958.2001.02532.x. PubMed DOI

Theophilus PA, Victoria MJ, Socarras KM, Filush KR, Gupta K, Luecke DF, et al. Effectiveness of Stevia rebaudiana whole leaf extract against the various morphological forms of Borrelia burgdorferi in vitro. Eur J Microbiol Immunol. 2015;5:268–280. doi: 10.1556/1886.2015.00031. PubMed DOI PMC

Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y. Selective essential oils from spice or culinary herbs have high activity against stationary phase and biofilm Borrelia burgdorferi. Front Med. 2017;4:169. doi: 10.3389/fmed.2017.00169. PubMed DOI PMC

Feng J, Shi W, Miklossy J, Tauxe GM, McMeniman CJ, Zhang Y. Identification of essential oils with strong activity against stationary phase Borrelia burgdorferi. Antibiotics. 2018;7:89. doi: 10.3390/antibiotics7040089. PubMed DOI PMC

Antigenicity and immunogenicity of different morphological forms of Borrelia burgdorferi sensu lato spirochetes

Pathogenicity and virulence of Borrelia burgdorferi

Concurrent Infection of the Human Brain with Multiple Borrelia Species

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

Seroprevalence of Antibodies against Tick-Borne Pathogens in Czech Patients with Suspected Post-Treatment Lyme Disease Syndrome

Novel targets and strategies to combat borreliosis